Results 61 to 70 of about 5,756 (231)
Cyclic Peptides for Drug Development
Angewandte Chemie, Volume 136, Issue 3, January 15, 2024.Cyclic peptides combine a number of favorable properties that make them attractive for drug development. Today, more than 40 therapeutics based on cyclic peptides are in use, and new, powerful technologies for their development suggest that this number could grow rapidly.
Xinjian Ji +2 more
wiley +2 more sources
A disintegrin derivative as a case study for PHIP labeling of disulfide bridged biomolecules
Scientific Reports, 2022 A specific labeling strategy for bioactive molecules is presented for eptifibatide (integrilin) an antiplatelet aggregation inhibitor, which derives from the disintegrin protein barbourin in the venom of certain rattlesnakes. By specifically labeling the
Max Fleckenstein +7 more
doaj +1 more source
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention [PDF]
, 2002 ObjectivesThis study was designed to examine a unique and low dose of intravenous enoxaparin in elective percutaneous coronary intervention (PCI) that would be applicable to an unselected population regardless of age, weight, renal function, or use of ...
Ankri, Annick +8 more
core +1 more source
A critical review of therapeutic interventions in sickle cell disease: Progress and challenges
Archiv der Pharmazie, Volume 357, Issue 11, November 2024.Sickle cell disease reflects a complex interplay of genetics, hematology, and clinical symptoms. The intricate pathogenesis of the disease offers a landscape with various targets and treatment options. Anticipated advancements in treatment include combining fetal hemoglobin inducers with other drug classes to improve the efficacy beyond monotherapy ...
Chandu Ala +6 more
wiley +1 more source
Immediate outcomes of eptifibatide therapy during intracoronary stent implantation
Advanced Biomedical Research, 2016 Background: The objective of the present study was to assess the major immediate outcomes of eptifibatide therapy during intracoronary stent implantation.
Hooman Shariati +4 more
doaj +1 more source
Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade. [PDF]
PLoS ONE, 2012 PurposeEnd-organ apoptosis is well-described in progressive sepsis and Multiple Organ Dysfunction Syndrome (MODS), especially where platelets accumulate (e.g. spleen and lung).
Matthew Sharron +7 more
doaj +1 more source
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease [PDF]
, 2001 Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials
Salam, Amar M, Suwaidi, Jassim Al
core +3 more sources
Journal of Peptide Science, Volume 30, Issue 11, November 2024.This review provides an overview of FDA‐approved peptides, particularly those targeting cardiovascular diseases, human immunodeficiency, and central nervous system diseases, and also addresses conditions such as osteoporosis, thrombocytopenia, Cushing's disease, and hypoglycemia.
Othman Al Musaimi
wiley +1 more source
Рациональная фармакотерапия в кардиологии, 2020 Recently, there has been a positive trend to reduce mortality from myocardial infarction. One of the reasons for such dynamics is the development of angiographic service in our country and the increase in the number of primary percutaneous coronary ...
A. S. Tereshchenko +2 more
doaj +1 more source
Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. [PDF]
PLoS ONE, 2014 The mainstay of treatment for thrombosis, the formation of occlusive platelet aggregates that often lead to heart attack and stroke, is antiplatelet therapy. Antiplatelet therapy dosing and resistance are poorly understood, leading to potential incorrect
Melissa Li +3 more
doaj +1 more source